DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells

Cancer Research

Volumn 56, Issue 20, 1996, Pages 4715-4723

  Matsui, Sei Ichi ^a,b   Arredondo, Mark A ^a,b   Wrzosek, Carol ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RALTITREXED;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; COLON CARCINOMA; DNA DAMAGE; DNA REPLICATION; DNA SYNTHESIS; GENE INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE; CELL DIVISION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; DNA REPLICATION; DNA, NEOPLASM; G1 PHASE; G2 PHASE; HUMANS; NEOPLASM PROTEINS; QUINAZOLINES; S PHASE; THIOPHENES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029841372     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Friedkin, M. Thymidylate synthetase. Adv. Enzymol. Relat. Areas Mol. Biol., 38: 235-292, 1973.
2. Harrap, K. R. Initiatives with platinum- and quinazoline-based antitumor molecules Cancer Res, 55. 2761-2768, 1995
3. Bisset, G M F., Pawelczak, K., Jackman, A. L, and Calvert, A. H. Syntheses and thymidylate synthase inhibitory activity of the poly-t-glutamyl conjugates of N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2- thenoyl]-L-glutamic acid (ICI D1694) and other quinazoline antifolates. J Med. Chem., 35 859-866, 1992.
4. Clarke, S, Ward, J., Planting, A., Sipers, J., Smioth, R, Verveij, J, and Judson, I. Phase I trial of ICI D1694: a novel thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res., 33: 406, 1992.
5. Jodrell, D. I., Newell, D. R., Gibson, W, Hughes, L. R., and Calvert, A. H. The pharmacokinetics of the quinazoline antifolate ICI D1694 in mice and rats. Cancer Chemother Pharmacol, 28. 331-338, 1991.
6. Ward, W. H., Kimbell, R., and Jackman, A L. Kinetic characteristics of ICI D1694. a quinazoline antifolate which inhibits thymidylate synthase. Biochem Pharmacol., 43: 2029-2031, 1992.
7. Gibson, W., Bisset, G M. F., Marsham, P. R., Kelland, L. R., Judson, I. R., and Jackman, A L The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells. Biochem. Pharmacol., 45: 863-869, 1993
8. Jackman, A L. ICT D1694: mechanism of action. In: Y. Rustum (ed), International Symposium on Novel Approaches to Selective Treatment of Human Solid Tumors: Laboratory and Clinical Correlation, pp. 76-78, 1992.
9. Jackman, A L., Taylor, G. A., Gibson, W, Kimbell, R., Brown, M., Calvert, A. H., Judson, I R, and Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo, a new agent for clinical study Cancer Res, 57: 5579-5586, 1991.
10. Keyomarsi, K., Samet, J., Molnar, G., and Pardee, A. B. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J. Biol. Chem, 268: 15142-15149, 1993
11. Yin, M. B., Guimaraes, M. A, Zhang, Z G., Arredondo, M. A., and Rustum, Y. M. Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor. Cancer Res, 52: 5900-5905, 1992.
12. Lu, K, Yin, M. B., McGuire, J J Ronnamassar, E., and Rustum, Y. M. Mechanism of resistance of N-[5-[N-3,4-dihydro-2-methyl-4-oxoquinazoline-6-ylmethyl)-N-methylamino]-2- thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line Biochem. Pharmacol, 50: 391-398, 1995.
13. Jackman, A.I, Gibson, W., Brown, M., Kimbell, R., and Boyle, F T. The role of the reduced folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv Exp. Med. Biol., 339: 265-276, 1993.
14. Clarke, S. J., Jackman, A. L., and Judson, I R The toxicity of ICI D1694 in man and mouse. Adv Exp. Med. Biol., 338. 601-604, 1993
15. Touroutoglou, N., and Pazdur, R Thymidylate synthase inhibitors. Clin. Cancer Res., 2 227-243, 1996
16. Cantwell, B. M., Macaulay, W, Harns, A. L., Kaye, S. B., Smith, I. E, Mistead, R A. V., and Calvert, A. M. Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB3171) in advanced breast cancer. Eur. J. Cancer Clin. Oncol., 24: 733-736, 1988
17. Calvert, A. H., Alison, D. L., Harland, S. J., Robinson, R. A, Jackman, A L, Jones, T. R, Newell, D. R., Siddik, A. H., Wiltshaw, E., McElwarin, T. J., Smith, I. E, and Harrap, K. R J. A phase I evaluation of the quinazoline anti-folate thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid, CB3717. Clin. Oncol, 4: 1245-1252, 1986.
18. Jodrell, D. I., Newell, D R., Morgan, S, E., Clinton, S., Benste, D. J. P. M., Hughes, L. R., and Calvert, A. H. The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue, ICI D1694, in mice Br. J. Cancer, 64: 833-838, 1991.
19. Jones, T. R, Calvert, A. H., Jackman, A. L., Brown, S. J., Jones, H., and Harrap, K R. A potent antitumor quinazoline inhibitor of thymidylate synthetase. I Synthesis, biological properties, and therapeutic results in mice. Eur J Cancer, 17: 11-19, 1981.
20. Arredondo, M. A., Guimaraes, M. A., Yin, M. B., Slocum, H. K., and Rustum, Y. M. Prolonged cell-cycle phase perturbation induced by the quinazoline antifolate thymidylate synthase inhibitor, ICI D1694 Proc. Am. Assoc. Cancer Res., 33: 428, 1992.
21. Arredondo, M. A., Yin, M. B., Lu, K., Schoeber, C., Slocum, H K, and Rustum, Y M Decreased c-myc protein accompanied by increased p53 and Rb is associated with thymidylate synthase inhibition and cell cycle retardation induced by D1694. Proc. Am. Assoc Cancer Res., 35: 304, 1994.
22. Skelton, L. A., Kimbell, R., Brunton, L. A., Titley, J., Aheme, G. M. W., Hardcastle, A., Bolyle, F. T, and Jackman, A. L. 2-Pyridyl-quinazoline as inhibitors of thymidylate synthase (TS) Proc Am. Assoc. Cancer Res, 35: 301, 1994.
23. Matsui, S., Lu, K., Wrzosek, C., and Rustum, Y. Double-strand DNA damage induced by thymidylate synthase (TS) inhibitor, ZD1694, in human colon carcinoma cell, HCT-8, requires DNA replication. Proc. Am. Assoc. Cancer Res., 36 378, 1995.
24. Kastan, M. B., Onyekwere, O., Sidransky, D, Vogelstein, B., and Carig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991
25. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age Cell, 79. 573-582, 1994.
26. 1 arrest and apoptosis. Cancer Res, 54: 1169-1174, 1994
27. Nakanishi, M, Robertorye, R S, Pereira-Smith, O. M., and Smith, J. R. The C-terminal region of p21P21/Waf-1/Cip1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. J Biol. Chem, 270. 17060-17063, 1995.
28. Waga, S, Hannon, G. J., Beach, D., and Stillman, B The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interacting with PCNA. Nature (Lond.), 369. 574-578, 1994.
29. Matsui, S., Arredondo, M, Toth, K., Minderman, H, Wrzosek, C., and Rustum, Y. ZD1694-induced cell cycle arrest in human colon carcinoma cell lines expressing wild and mutant p53. Proc. Am Assoc. Cancer Res., 36: 31, 1995
30. Judson, J, Clarke, S., Ward, J, Sutcliffe, F., Planting, A., Spiers, J., Smith, R., Verweij, J., and Judson, I. Pharmacokinetics of ICI D1694 following a 15 minute infusion in patients with advanced cancer Proc. Am. Soc. Clin. Oncol Annu. Meet, 11: 117, 1992.
31. Clarke, S. J, Ward, J., Tierney, K, Walker, M., Sutcliffe, F., Planting, A., Verweij, J., Spiers, J, Smith, R., and Judson, I. Phase I and pharmacokinetic study of ICI D1694 a folate-based thymidylate synthase (TS) inhibitor. Ann. Oncol, 3 (Suppl. I): 135, 1992.
32. Miller, E M., and Kinsella, T. J Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization. Cancer Res., 52. 1687-1694, 1992.
33. Matsui, S., Yoshida, H., Weinfeld, H., and Sandberg, A. A Induction of prophase in interphase nuclei by fusion with metaphase cells. J Cell Biol, 54: 120-134, 1972.
34. Matsui, S., Weinfeld, H., and Sandberg, A. A. Quantitative conservation of chromatin-bound RNA polymerase I and II in mitosis: implications for chromosome structure. J. Cell Biol., 80: 451-464, 1979
35. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage TH. Nature (Lond), 227: 680-685, 1994
36. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, D, and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res, 51: 6304-6311, 1991
37. Vogelstein, B., and Kinzler, K W. p53 function and dysfunction. Cell. 70: 523-526, 1992.
38. O'Connor, P. M, Jackman, J., Jondle, D Bhata, K., Magrath, I., and Kohn, K. W. Role of the p53 suppressor gene in cell cycle arrest in radiosensitivity of Bukitt's lymphoma cell lines. Cancer Res, 53: 4776-4780, 1993
39. Kuerbitz, S. J, Plunkett, B. S., Walsh, W. V., and Kastan, M B. Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
40. Kwok, T T., Mok, C H, and Menton-Brennan, L. Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells Cancer Res, 54: 2834-2838, 1994
41. 2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2 kinase complexes differently. J. Biol Chem., 268: 8298-8308, 1993.
42. 2 delay Cancer Res., 55: 1643-1648, 1995.
43. Hawkins, D S, Demers, G. W., and Galloway, D A Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res, 56. 892-898, 1996.
44. 1 arrest in human cancer cells. Cancer Res., 55: 5187-5190, 1995
45. Curtin, N. J., Harris, A L., and Aherne, G W. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res., 57: 2346-2352, 1991
46. Pressacco, J., Mitrovski, B, Erlichman, C, and Hedley, D W. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res., 55 1505-1508, 1995.
47. CIP1 is not required for the early G2 checkpoint response to ionizing radiation Cancer Res, 55 2500-2502, 1995.
48. 1 phase arrest and p53 function in human tumor cells Cancer Res., 55: 1842-1846, 1995.
49. Lu, X., and Lane, D P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75: 765-778, 1993
50. Lindahl, T. DNA glycosylases, endonucleases for apurinic/apyrimidinic sites, and base excision-repair. Prog. Nucleic Acids Res. Mol Biol., 22: 135-192, 1979
51. Sedwick, W. D., Kutler, M., and Brown, O. E. Antifolate-induced misincorporation of deoxyuridine monophosphate into DNA: inhibition of high molecular weight DNA synthesis in human lymphoblastoid cells. Proc. Natl. Acad. Sci. USA, 78: 917-921, 1981
52. Canman, C. E., Tang, H-Y., Normalle, D. P., Lawrence, T S, and Maybaum, J. Variation in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine-implications for mechanisms of resistance and cytotoxicity. Proc. Natl. Acacd. Sci. USA, 89: 10474-10478, 1992.
53. Canman, C E., Lawrence, T. S., Shewach, D. S Tang, H-Y., and Maybaum, J. Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of dexoyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate Cancer Res., 53: 5219-5224, 1993.
54. Chu, G Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem., 269: 787-790, 1994